{"prompt": "['PROTOCOL SCHEMA', 'Figure 1. Proposed study procedure and timeline', '3 months off', 'Timeline', 'Pre Tx', 'Post 3 cycles of', 'End of', 'therapy', 'Evaluation', 'BV', 'therapy', 'Proposed', 'Safety', 'FACT-G QoL', 'FACT-G QoL FACT-G QoL', 'studies', 'Laboratory1,2', 'Echo', 'AE evaluation\u00b2', 'KS response', 'evaluation\u00b2', 'CD4 count', 'FACT-G QoL', '1.', 'Laboratory studies to include CBC, total bilirubin, SGOT [AST], , Creatinine,', '2. To be evaluated prior to each treatment cycle', 'AMC-S007 (Version 2.0) 20MAR2018', '8', 'NCI Version Date 20MAR2018']['ABBREVIATIONS LIST', 'ABV', 'adriamycin, bleomycin, and vincristine', 'AE', 'adverse event', 'AERS', 'Adverse Event Reporting System', 'AIDS', 'acquired immunodeficiency syndrome', 'ALT', 'alanine aminotransferase', 'AMC', 'AIDS Malignancy Consortium', 'AML', 'acute myelocytic leukemia', 'ANC', 'absolute neutrophil count', 'ART', 'antiretroviral therapy', 'AST', 'aspartate aminotransferase', 'BIP', 'bleomycin-induced pneumonitis', 'BMC', 'Bugando Medical Centre', 'BV', 'bleomycin and vincristine sulfate', 'cART', 'combined antiretroviral therapy', 'CBC', 'complete blood count', 'CDC', 'Centers for Disease Control and Prevention', 'CDUS', 'Clinical Data Update System', 'COPD', 'chronic obstructive pulmonary disease', 'CR', 'complete response', 'CRF', 'case report form', 'CT', 'computed tomography', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'CTEP', 'Cancer Therapy Evaluation Program', 'CTMS', 'Clinical Trials Monitoring Service', 'CXR', 'chest x-ray', 'DHHS', 'Department of Health and Human Services', 'DNA', 'deoxyribonucleic acid', 'ECOG', 'Eastern Cooperative Oncology Group', 'FACT-G', 'Functional Assessment of Cancer Therapy-General', 'FCBP', 'female of childbearing potential', 'FDA', 'Food and Drug Administration', 'G-CSF', 'granulocyte colony stimulating factor', 'HAART', 'highly active antiretroviral therapy', 'HHV-8', 'human herpesvirus-8', 'HIV', 'human immunodeficiency virus', 'AMC-S007 (Version 2.0) 20MAR2018', '9', 'NCI Version Date 20MAR2018']['ICH', 'International Conference on Harmonisation', 'IDB', 'Investigational Drug Branch', 'IEC', 'institutional ethics committee', 'IND', 'investigational new drug', 'INR', 'international normalized ratio', 'IRB', 'institutional review board', 'KPS', 'Karnofsky performance status', 'KS', 'Kaposi sarcoma', 'KSHV', 'Kaposi sarcoma-associated herpesvirus', 'LFT', 'liver function test', 'LLN', 'lower limit of normal', 'MDS', 'myelodysplastic syndrome', 'MOP', 'manual of procedures', 'NCI', 'National Cancer Institute', 'NIMR', 'National Institute for Medical Research', 'NRTI', 'nucleoside reverse transcriptase inhibitor', 'ODMC', 'Operations and Data Management Center', 'OHAM', 'Office of HIV and AIDS Malignancy', 'OTC', 'over the counter', 'PCP', 'Pneumocystis jirovecii pneumonia', 'PD', 'progressive disease', 'PI', 'principal investigator', 'PIO', 'Protocol Information Office', 'PLD', 'pegylated liposomal doxorubicin', 'PN', 'peripheral neuropathy', 'PR', 'partial response', 'prn', 'pro re nata (as needed)', 'QOL', 'quality of life', 'RNA', 'ribonucleic acid', 'SAE', 'serious adverse event', 'SD', 'stable disease', 'SGOT', 'serum glutamic oxaloacetic transaminase', 'SGPT', 'serum glutamic pyruvic transaminase', 'SOC', 'System Organ Class', 'ULN', 'upper limit of normal', 'WHO', 'World Health Organization', 'AMC-S007 (Version 2.0) 20MAR2018', '10', 'NCI Version Date 20MAR2018']\n\n###\n\n", "completion": "END"}